US FDA calls Abbott's Depakote promotion misleading
This article was originally published in Scrip
Executive Summary
A flashcard used in the promotion of Abbott’s anti-epileptic Depakote (divalproex sodium delayed-release) tablets and Depakote ER (divalproex sodium extended-release) tablets is misleading, the US FDA says.